We investigated the effects of copper (Cu) and iron (Fe) availability on the growth rates, cellular Cu content, and steady-state Cu uptake rates of eight species of centric diatoms (coastal and oceanic strains). Whereas Fe and Cu availability had a significant effect on the growth rates of both costal and oceanic diatoms, an interaction between Fe and Cu availability and growth rates was only observed for the oceanic diatoms. Determination of cellular Cu : carbon (C) quotas using the radiotracers 67 Cu and 14 C revealed that under Cu-sufficient conditions oceanic diatoms had elevated Cu : C ratios relative to coastal strains, regardless of Fe availability. Two species (one oceanic and one coastal) significantly increased their Cu demands in response to Fe limitation, indicating upregulation of the Cu-dependent high-affinity Fe uptake system in these organisms. The changes in cellular Cu : C ratios were accompanied by variations in steady-state Cu uptake rates. Thus, in some cases Cu uptake rates appear to be regulated by the cell in response to Fe availability. Rates of Cu acquisition also responded significantly to Cu variability. The variation in Cu uptake was more closely correlated with changes in total Cu concentration in the medium than in inorganic, free Cu concentrations, implying that organic Cu complexes may be bioavailable to diatoms. These findings indicate a greater biological role for Cu than was previously thought in open ocean regions.
Purpose To evaluate safety, human radiation dosimetry and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. Procedures Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab-PET/CT twice within 7 days postinjection. Biodistribution data from whole-torso PET/CT images, and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. Results High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day postinjection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in 10 patients. The liver was the dose-limiting organ (retention of ~12% of the injected dose and average dose of 1.54 mSv/MBq. The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. Conclusion [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy. Although 111In-labeled caprop-mab pendetide is the only approved agent available for PSMA imaging, its clinical use is limited because of its slow distribution and clearance that leads to challenging image interpretation. A small-molecule approach using radiolabeled urea-based PSMA inhibitors as imaging agents has shown promise for prostate cancer imaging. The motivation of this work is to explore phosphoramidates as a new class of potent PSMA inhibitors to develop more effective prostate cancer imaging agents with improved specificity and clearance properties. Methods N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) was conjugated to S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid (Phosphoramidate (1)), yielding S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid (3). In vivo studies were conducted in mice bearing either LNCaP (PSMA-positive) or PC-3 (PSMA-negative) tumors. PET images were acquired at 1 and 2 h with or without a preinjection of a nonradioactive version of the fluorophosphoramidate. Tissue distribution studies were performed at the end of the 2 h imaging sessions. Results Phosphoramidate (1) and its fluorobenzamido conjugate (2) were potent inhibitors of PSMA (inhibitory concentration of 50% [IC50], 14 and 0.68 nM, respectively). PSMA-mediated tumor accumulation was noted in the LNCaP versus the PC-3 tumor xenografts. The LNCaP tumor uptake was also blocked by the administration of nonradioactive (2) prior to imaging studies. With the exception of the kidneys, tumor-to-tissue and tumor-to-blood ratios were greater than 5:1 at 2 h. The strong kidney uptake may be due to the known PSMA expression in the mouse kidney, because significant reduction (>6-fold) in kidney activity was seen in mice injected with (2). Conclusion 18F-labeled phosphoramidate (3) is a representative of a new class of PSMA targeting peptidomimetic molecules that shows great promise as imaging agents for detecting PSMA+ prostate tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.